Author:
Stève-Dumont M.,Chemin M.,Taouss O.,Vergely L.
Reference19 articles.
1. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis;Edwards;N Engl J Med,2004
2. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomised, double-blind placebo-controlled, dose ranging trial;Emery;Arthritis Rheum,2006
3. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum.,2006
4. Maravic M, Mouterde G, Favre-Bonté J. Recommandation HAS polyarthrite rhumatoïde. Medec 2008.
5. Afssaps Référentiel national de bon usage du Rituximab. Version 1. Avril 2008.